Tom Nevins - Hoffmann-La Roche Inc | 人才画像

基本信息

浏览量：6

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 11 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplementary Figure 2 from RG7212 Anti-TWEAK Mab Inhibits Tumor Growth Through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

Xingtian Yin,Leopoldo Luistro,Hua Zhong,Melissa Smith,Tom Nevins,Kathleen Schostack,Holly Hilton, Tao Lin, Theresa Truitt, Denise Biondi,Xiaoqian Wang,Kathryn Packman, J. Rosiński,Windy Berkofsky‐Fessler,Jianping Tang,Saumya Pant,David Geho,Suzana Vega-Harring,Mark DeMario,Hy Levitsky,Mary Ellen Simcox

openalex

引用0浏览0引用

Identification of Novel, Potent and Selective Inhibitors of Polo-like Kinase 1

Shaoqing Chen,David Bartkovitz,Jianping Cai,Yi Chen,Zhi Chen,Xin-Jie Chu,Kang Le,Nam T. Le,Kin-Chun Luk,Steve Mischke,Goli Naderi-Oboodi,John F. Boylan,Tom Nevins,Weiguo Qing,Yingsi Chen,Peter M. Wovkulich

Bioorganic & medicinal chemistry letters（2012）

引用34浏览0WOS引用

High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097

Wei He,Leopoldo Luistro,Daisy Carvajal,Melissa Smith,Tom Nevins,Xuefeng Yin,James Cai,Brian Higgins,Kenneth Kolinsky,Christine Rizzo,Kathryn Packman,David Heimbrook,John F Boylan

Molecular oncologyno. 3 (2011): 292-301

引用42浏览0WOS引用

High Tumor Levels Of Il6 And Il8 Abrogate Preclinical Efficacy Of The Gamma-Secretase Inhibitor, Ro4929097

Wei He,Leopoldo Luistro,Daisy Carvajal,Melissa Smith,Tom Nevins,Xuefeng Yin,James Cai,Brian Higgins,Kenneth Kolinsky,Christine Rizzo,Kathryn Packman,David Heimbrook,John F. Boylan

MOLECULAR ONCOLOGYno. 3 (2011): 292-301

引用39浏览0引用

In Vitro and in Vivo Activity of R547: a Potent and Selective Cyclin-Dependent Kinase Inhibitor Currently in Phase I Clinical Trials

Wanda DePinto,Xin-Jie Chu,Xuefeng Yin,Melissa Smith,Kathryn Packman,Petra Goelzer,Allen Lovey,Yingsi Chen,Hong Qian, Rachid Hamid, Qing Xiang,Christian Tovar, Roger Blain,Tom Nevins,Brian Higgins,Leopoldo Luistro,Kenneth Kolinsky, Bernardo Felix,Sazzad Hussain,David Heimbrook

Molecular cancer therapeutics（2006）

引用102浏览0WOS引用

102

A novel and selective CDK inhibitor shows potent in vivo anti-tumor activity that correlates with inhibition of phospho-Rb

Wanda DePinto,Xuefeng Yin,Christian Tovar,Melissa Smith,Tom Nevins,Kathryn Packman,Allen John Lovey,Xin-Jie Chu,Petra Goelzer,Sazzad Hussain, Eric Kraft, Roger Blain,Yingsi Chen

Cancer Research（2005）

引用23浏览0引用

RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: Synthesis and biological evaluation

Lee A. McDermott,Mary Simcox,Brian Higgins,Tom Nevins,Kenneth Kolinsky,Melissa Smith,Hong Yang,Jia K. Li,Yingsi Chen,June Ke,Navita Mallalieu,Tom Egan,Stan Kolis,Aruna Railkar,Louise Gerber,Kin-Chun Luk

Bioorganic & Medicinal Chemistry（2005）

引用30浏览0EIWOS引用

Supplementary Figure 1 from RG7212 Anti-TWEAK Mab Inhibits Tumor Growth Through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

Xingtian Yin,Leopoldo Luistro,Hua Zhong,Melissa Smith,Tom Nevins,Kathleen Schostack,Holly Hilton, Tao Lin, Theresa Truitt, Denise Biondi,Xiaoqian Wang,Kathryn Packman, J. Rosiński,Windy Berkofsky-Fessler,Jianping Tang,Saumya Pant,David Geho,Suzana Vega-Harring,Mark DeMario,Hy Levitsky,Mary Ellen Simcox

openalex

引用0浏览0引用

Supplementary Figure Legends and Table Legends and Methods from RG7212 Anti-TWEAK Mab Inhibits Tumor Growth Through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

Xingtian Yin,Leopoldo Luistro,Hua Zhong,Melissa Smith,Tom Nevins,Kathleen Schostack,Holly Hilton, Tao Lin, Theresa Truitt, Denise Biondi,Xiaoqian Wang,Kathryn Packman,J. Rosiński,Windy Berkofsky‐Fessler,Jianping Tang,Saumya Pant,David Geho,Suzana Vega-Harring,Mark DeMario,Hy Levitsky,Mary Ellen Simcox

openalex

引用32浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn